-$425.2M
Net Activity
Institutions Holding
253
Popularity Rank
#2342
Avg Weight
0.17%
Total Value
$3.2B
253 institutions currently hold TARS, with 129 net buyers and 120 net sellers this quarter.
Institutional Moves (Q1 2026)
Neutral
Based on recent trading activity
Net Selling Institutions
120
Net Buying Institutions
129
Top 5 by Value
+$1.5B
Total Buy Value
$1.6B
Total Sell Value
129
Net Buyers
120
Net Sellers
4
Filings (90d)
$2.45M
Total Est. Value
40K shares
Planned Shares
| Filer | Filing Date | Est. Value |
|---|---|---|
| Azamian Bobak R. | 2026-06-17 | $615K |
| Farrow Jeffrey S | 2026-06-16 | $877K |
| Goodrich Katherine | 2026-06-15 | $183K |
| LINK WILLIAM J PHD | 2026-06-15 | $776K |
Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker。
No Schedule 13D/13G filings for this ticker
2
Filings (14d)
Tarsus Pharmaceuticals announced on July 13 that Chief Commercial Officer Aziz Mottiwala is leaving the company on July 15 to become CEO of a public medical device company. The disclosure was made in an 8-K filing.
View Full Filing (SEC EDGAR)Tarsus Pharmaceuticals acquired iRenix Medical on July 6, 2026, paying $37.5 million in cash and 607,093 shares of TARS common stock upfront. Additional payments of up to $490 million hinge on hitting regulatory and commercial milestones, plus low-to-mid single-digit revenue sharing on certain future product net sales. iRenix now operates as a wholly owned subsidiary of Tarsus.
View Full Filing (SEC EDGAR)The most-added stocks by 13F institutions this quarter
Institutions Holding
6,150
Total reported value
$2.1T
3245 13F institutions increased their position this quarter
Institutions Holding
5,957
Total reported value
$1.5T
3028 13F institutions increased their position this quarter
Institutions Holding
5,764
Total reported value
$3.0T
2743 13F institutions increased their position this quarter